{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:15:29Z","timestamp":1795076129564,"version":"4.10.2"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7966","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nonsense mutations are the underlying cause of approximately 11% of all inherited genetic diseases\n                    <jats:sup>1<\/jats:sup>\n                    . Nonsense mutations convert a sense codon that is decoded by tRNA into a premature termination codon (PTC), resulting in an abrupt termination of translation. One strategy to suppress nonsense mutations is to use natural tRNAs with altered anticodons to base-pair to the newly emerged PTC and promote translation\n                    <jats:sup>2\u20137<\/jats:sup>\n                    . However, tRNA-based gene therapy has not yielded an optimal combination of clinical efficacy and safety and there is presently no treatment for individuals with nonsense mutations. Here we introduce a strategy based on altering native tRNAs into\u00a0 efficient suppressor tRNAs (sup-tRNAs) by individually fine-tuning their sequence to the physico-chemical properties of the amino acid that they carry. Intravenous and intratracheal lipid nanoparticle (LNP) administration of sup-tRNA in mice\u00a0restored the production of functional proteins with nonsense mutations. LNP\u2013sup-tRNA formulations caused no discernible readthrough at endogenous native stop codons, as determined by ribosome profiling. At clinically important PTCs in the cystic fibrosis transmembrane conductance regulator gene (\n                    <jats:italic>CFTR<\/jats:italic>\n                    ), the sup-tRNAs re-established expression and function in cell systems and patient-derived nasal epithelia and restored airway volume homeostasis. These results provide a framework for the development of tRNA-based therapies with a high molecular safety profile and high efficacy in targeted PTC suppression.\n                  <\/jats:p>","DOI":"10.1038\/s41586-023-06133-1","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T12:04:45Z","timestamp":1685534685000},"page":"842-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Engineered tRNAs suppress nonsense mutations in cells and in vivo"],"prefix":"10.1038","volume":"618","author":[{"given":"Suki","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-0325","authenticated-orcid":false,"given":"Nikhil","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6230-3654","authenticated-orcid":false,"given":"Marcos","family":"Davyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-4850","authenticated-orcid":false,"given":"Carlos G.","family":"Perez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-8098","authenticated-orcid":false,"given":"Leonardo","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Mukthavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-1511","authenticated-orcid":false,"given":"Miguel Angel","family":"Delgado-Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Kuakini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Alayyoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9703-1975","authenticated-orcid":false,"given":"Kyoung-Joo Jenny","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grishma","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Birket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo J.","family":"Tearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-3354","authenticated-orcid":false,"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-2267","authenticated-orcid":false,"given":"Pad","family":"Chivukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-8825","authenticated-orcid":false,"given":"Zoya","family":"Ignatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"6133_CR1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","volume":"29","author":"M Mort","year":"2008","unstructured":"Mort, M., Ivanov, D., Cooper, D. N. & Chuzhanova, N. A. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 29, 1037\u20131047 (2008).","journal-title":"Hum. Mutat."},{"key":"6133_CR2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/ejhg.2013.292","volume":"22","author":"R Bordeira-Carrico","year":"2014","unstructured":"Bordeira-Carrico, R. et al. Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. Eur. J. Hum. Genet. 22, 1085\u20131092 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"6133_CR3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/281602a0","volume":"281","author":"JC Chang","year":"1979","unstructured":"Chang, J. C., Temple, G. F., Trecartin, R. F. & Kan, Y. W. Suppression of the nonsense mutation in homozygous \u03b20 thalassaemia. Nature 281, 602\u2013603 (1979).","journal-title":"Nature"},{"key":"6133_CR4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","volume":"10","author":"JD Lueck","year":"2019","unstructured":"Lueck, J. D. et al. Engineered transfer RNAs for suppression of premature termination codons. Nat. Commun. 10, 822 (2019).","journal-title":"Nat. Commun."},{"key":"6133_CR5","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","volume":"12","author":"JJ Porter","year":"2021","unstructured":"Porter, J. J., Heil, C. S. & Lueck, J. D. Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip. Rev. RNA 12, e1641 (2021).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"6133_CR6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/296537a0","volume":"296","author":"GF Temple","year":"1982","unstructured":"Temple, G. F., Dozy, A. M., Roy, K. L. & Kan, Y. W. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for \u03b2-thalassaemia. Nature 296, 537\u2013540 (1982).","journal-title":"Nature"},{"key":"6133_CR7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","volume":"604","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature 604, 343\u2013348 (2022).","journal-title":"Nature"},{"key":"6133_CR8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/jcm9020289","volume":"9","author":"M Borgatti","year":"2020","unstructured":"Borgatti, M., Altamura, E., Salvatori, F., D'Aversa, E. & Altamura, N. Screening readthrough compounds to suppress nonsense mutations: possible application to \u03b2-thalassemia. J. Clin. Med. 9, 289 (2020).","journal-title":"J. Clin. Med."},{"key":"6133_CR9","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","volume":"12","author":"J Sharma","year":"2021","unstructured":"Sharma, J. et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat. Commun. 12, 4358 (2021).","journal-title":"Nat. Commun."},{"key":"6133_CR10","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","volume":"113","author":"B Roy","year":"2016","unstructured":"Roy, B. et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc. Natl Acad. Sci. USA 113, 12508\u201312513 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6133_CR11","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/nar\/gkac222","volume":"50","author":"E Westhof","year":"2022","unstructured":"Westhof, E., Thornlow, B., Chan, P. P. & Lowe, T. M. Eukaryotic tRNA sequences present conserved and amino acid-specific structural signatures. Nucleic Acids Res. 50, 4100\u20134112 (2022).","journal-title":"Nucleic Acids Res."},{"key":"6133_CR12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.abi7801","volume":"373","author":"MR Lawson","year":"2021","unstructured":"Lawson, M. R. et al. Mechanisms that ensure speed and fidelity in eukaryotic translation termination. Science 373, 876\u2013882 (2021).","journal-title":"Science"},{"key":"6133_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature14896","volume":"524","author":"A Brown","year":"2015","unstructured":"Brown, A., Shao, S., Murray, J., Hegde, R. S. & Ramakrishnan, V. Structural basis for stop codon recognition in eukaryotes. Nature 524, 493\u2013496 (2015).","journal-title":"Nature"},{"key":"6133_CR14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41580-019-0118-2","volume":"20","author":"CAP Joazeiro","year":"2019","unstructured":"Joazeiro, C. A. P. Mechanisms and functions of ribosome-associated protein quality control. Nat. Rev. Mol. Cell Biol. 20, 368\u2013383 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"6133_CR15","doi-asserted-by":"crossref","first-page":"a032862","DOI":"10.1101\/cshperspect.a032862","volume":"11","author":"ED Karousis","year":"2019","unstructured":"Karousis, E. D. & Muhlemann, O. Nonsense-mediated mRNA decay begins where translation ends. Cold Spring Harb. Perspect. Biol. 11, a032862 (2019).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"6133_CR16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41580-018-0011-4","volume":"19","author":"AP Schuller","year":"2018","unstructured":"Schuller, A. P. & Green, R. Roadblocks and resolutions in eukaryotic translation. Nat. Rev. Mol. Cell Biol. 19, 526\u2013541 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"6133_CR17","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-021-24076-x","volume":"12","author":"S Albers","year":"2021","unstructured":"Albers, S. et al. Repurposing tRNAs for nonsense suppression. Nat. Commun. 12, 3850 (2021).","journal-title":"Nat. Commun."},{"key":"6133_CR18","doi-asserted-by":"crossref","first-page":"16333","DOI":"10.1073\/pnas.2004170117","volume":"117","author":"HA Nguyen","year":"2020","unstructured":"Nguyen, H. A., Sunita, S. & Dunham, C. M. Disruption of evolutionarily correlated tRNA elements impairs accurate decoding. Proc. Natl Acad. Sci. USA 117, 16333\u201316338 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6133_CR19","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.1102128108","volume":"108","author":"JM Schrader","year":"2011","unstructured":"Schrader, J. M., Chapman, S. J. & Uhlenbeck, O. C. Tuning the affinity of aminoacyl-tRNA to elongation factor Tu for optimal decoding. Proc. Natl Acad. Sci. USA 108, 5215\u20135220 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6133_CR20","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1016\/S0021-9258(18)67412-5","volume":"261","author":"M Yarus","year":"1986","unstructured":"Yarus, M., Cline, S., Raftery, L., Wier, P. & Bradley, D. The translational efficiency of tRNA is a property of the anticodon arm. J. Biol. Chem. 261, 10496\u201310505 (1986).","journal-title":"J. Biol. Chem."},{"key":"6133_CR21","doi-asserted-by":"crossref","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","volume":"114","author":"S Ramaswamy","year":"2017","unstructured":"Ramaswamy, S. et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl Acad. Sci. USA 114, E1941\u2013E1950 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6133_CR22","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1093\/nar\/gkw608","volume":"44","author":"H Grosjean","year":"2016","unstructured":"Grosjean, H. & Westhof, E. An integrated, structure- and energy-based view of the genetic code. Nucleic Acids Res. 44, 8020\u20138040 (2016).","journal-title":"Nucleic Acids Res."},{"key":"6133_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbpa.2018.07.016","volume":"46","author":"OC Uhlenbeck","year":"2018","unstructured":"Uhlenbeck, O. C. & Schrader, J. M. Evolutionary tuning impacts the design of bacterial tRNAs for the incorporation of unnatural amino acids by ribosomes. Curr. Opin. Chem. Biol. 46, 138\u2013145 (2018).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"6133_CR24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","volume":"199","author":"AF McCague","year":"2019","unstructured":"McCague, A. F. et al. Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis. Am. J. Respir. Crit. Care Med. 199, 1116\u20131126 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"6133_CR25","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02350-5","volume":"17","author":"E Costa","year":"2022","unstructured":"Costa, E., Girotti, S., Pauro, F., Leufkens, H. G. M. & Cipolli, M. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J. Rare Dis. 17, 188 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"6133_CR26","doi-asserted-by":"crossref","first-page":"e52611","DOI":"10.7554\/eLife.52611","volume":"9","author":"JR Wangen","year":"2020","unstructured":"Wangen, J. R. & Green, R. Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides. eLife 9, e52611 (2020).","journal-title":"eLife"},{"key":"6133_CR27","first-page":"523","volume":"10","author":"K Kariko","year":"2007","unstructured":"Kariko, K. & Weissman, D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr. Opin. Drug Discov. Dev. 10, 523\u2013532 (2007).","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"6133_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"6133_CR29","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).","journal-title":"Nat. Commun."},{"key":"6133_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6133_CR31","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1074\/jbc.M117.818526","volume":"293","author":"G Loughran","year":"2018","unstructured":"Loughran, G. et al. Stop codon readthrough generates a C-terminally extended variant of the human vitamin D receptor with reduced calcitriol response. J. Biol. Chem. 293, 4434\u20134444 (2018).","journal-title":"J. Biol. Chem."},{"key":"6133_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","volume":"83","author":"CL Ward","year":"1995","unstructured":"Ward, C. L., Omura, S. & Kopito, R. R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121\u2013127 (1995).","journal-title":"Cell"},{"key":"6133_CR33","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1038\/s41467-020-17974-z","volume":"11","author":"ED Karousis","year":"2020","unstructured":"Karousis, E. D., Gurzeler, L. A., Annibaldis, G., Dreos, R. & Muhlemann, O. Human NMD ensues independently of stable ribosome stalling. Nat. Commun. 11, 4134 (2020).","journal-title":"Nat. Commun."},{"key":"6133_CR34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","volume":"20","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki, T., Popp, M. W. & Maquat, L. E. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat. Rev. Mol. Cell Biol. 20, 406\u2013420 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"6133_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","volume":"28","author":"W Ko","year":"2022","unstructured":"Ko, W., Porter, J. J., Sipple, M. T., Edwards, K. M. & Lueck, J. D. Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs. Mol. Ther. Nucleic Acids 28, 685\u2013701 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"6133_CR36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1261\/rna.5147804","volume":"10","author":"KM Keeling","year":"2004","unstructured":"Keeling, K. M. et al. Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA 10, 691\u2013703 (2004).","journal-title":"RNA"},{"key":"6133_CR37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald, C. M. et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1489\u20131498 (2017).","journal-title":"Lancet"},{"key":"6133_CR38","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1021\/acsami.8b21398","volume":"11","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Shrivastava, S., Cleveland, R. O. & Rabbitts, T. H. Lipid\u2013mRNA nanoparticle designed to enhance intracellular delivery mediated by shock waves. ACS Appl. Mater. Interfaces 11, 10481\u201310491 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"6133_CR39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ejhg.2013.238","volume":"22","author":"L Masvidal","year":"2014","unstructured":"Masvidal, L. et al. Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis. Eur. J. Hum. Genet. 22, 784\u2013791 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"6133_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1513\/pats.200703-043BR","volume":"4","author":"SM Rowe","year":"2007","unstructured":"Rowe, S. M., Accurso, F. & Clancy, J. P. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc. Am. Thorac. Soc. 4, 387\u2013398 (2007).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"6133_CR41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.tig.2020.11.002","volume":"37","author":"F Supek","year":"2021","unstructured":"Supek, F., Lehner, B. & Lindeboom, R. G. H. To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases. Trends Genet. 37, 657\u2013668 (2021).","journal-title":"Trends Genet."},{"key":"6133_CR42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","volume":"71","author":"IJ Haq","year":"2016","unstructured":"Haq, I. J., Gray, M. A., Garnett, J. P., Ward, C. & Brodlie, M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax 71, 284\u2013287 (2016).","journal-title":"Thorax"},{"key":"6133_CR43","doi-asserted-by":"crossref","first-page":"e1002608","DOI":"10.1371\/journal.pgen.1002608","volume":"8","author":"C Floquet","year":"2012","unstructured":"Floquet, C., Hatin, I., Rousset, J. P. & Bidou, L. Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genet. 8, e1002608 (2012).","journal-title":"PLoS Genet."},{"key":"6133_CR44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1126\/science.aaq1067","volume":"359","author":"S Iwano","year":"2018","unstructured":"Iwano, S. et al. Single-cell bioluminescence imaging of deep tissue in freely moving animals. Science 359, 935\u2013939 (2018).","journal-title":"Science"},{"key":"6133_CR45","doi-asserted-by":"crossref","unstructured":"de Alwis, R. et al. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol. Ther. 291983 (2021).","DOI":"10.1101\/2020.09.03.280446"},{"key":"6133_CR46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0022-2836(86)90228-7","volume":"187","author":"N Sternberg","year":"1986","unstructured":"Sternberg, N., Sauer, B., Hoess, R. & Abremski, K. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. J. Mol. Biol. 187, 197\u2013212 (1986).","journal-title":"J. Mol. Biol."},{"key":"6133_CR47","volume":"4","author":"Q Lin","year":"2004","unstructured":"Lin, Q., Jo, D., Gebre-Amlak, K. D. & Ruley, H. E. Enhanced cell-permeant Cre protein for site-specific recombination in cultured cells. BMC Biotechnol. 4, 25 (2004).","journal-title":"BMC Biotechnol."},{"key":"6133_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/metabo10030113","volume":"10","author":"D Schultz","year":"2020","unstructured":"Schultz, D. et al. 16HBE cell lipid mediator responses to mono and co-infections with respiratory pathogens. Metabolites 10, 113 (2020).","journal-title":"Metabolites"},{"key":"6133_CR49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","volume":"18","author":"HC Valley","year":"2019","unstructured":"Valley, H. C. et al. Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells. J. Cyst. Fibros. 18, 476\u2013483 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"6133_CR50","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1097-2765(00)00122-2","volume":"6","author":"GR Andersen","year":"2000","unstructured":"Andersen, G. R. et al. Structural basis for nucleotide exchange and competition with tRNA in the yeast elongation factor complex eEF1A:eEF1B\u03b1. Mol. Cell 6, 1261\u20131266 (2000).","journal-title":"Mol. Cell"},{"key":"6133_CR51","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jmb.2009.01.021","volume":"386","author":"JM Schrader","year":"2009","unstructured":"Schrader, J. M., Chapman, S. J. & Uhlenbeck, O. C. Understanding the sequence specificity of tRNA binding to elongation factor Tu using tRNA mutagenesis. J. Mol. Biol. 386, 1255\u20131264 (2009).","journal-title":"J. Mol. Biol."},{"key":"6133_CR52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0022-2836(86)90362-1","volume":"192","author":"M Yarus","year":"1986","unstructured":"Yarus, M., Cline, S. W., Wier, P., Breeden, L. & Thompson, R. C. Actions of the anticodon arm in translation on the phenotypes of RNA mutants. J. Mol. Biol. 192, 235\u2013255 (1986).","journal-title":"J. Mol. Biol."},{"key":"6133_CR53","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/nar\/26.22.5017","volume":"26","author":"R Giege","year":"1998","unstructured":"Giege, R., Sissler, M. & Florentz, C. Universal rules and idiosyncratic features in tRNA identity. Nucl. Acids Res. 26, 5017\u20135035 (1998).","journal-title":"Nucl. Acids Res."},{"key":"6133_CR54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/meth.2000.1131","volume":"23","author":"C Kao","year":"2001","unstructured":"Kao, C., Rudisser, S. & Zheng, M. A simple and efficient method to transcribe RNAs with reduced 3\u2032 heterogeneity. Methods 23, 201\u2013205 (2001).","journal-title":"Methods"},{"key":"6133_CR55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ni0602-499","volume":"3","author":"M Jurk","year":"2002","unstructured":"Jurk, M. et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3, 499 (2002).","journal-title":"Nat. Immunol."},{"key":"6133_CR56","first-page":"12992","volume":"63","author":"K Rajappan","year":"2020","unstructured":"Rajappan, K. et al. Property-driven design and development of lipids for efficient delivery of siRNA. J. Biol. Chem. 63, 12992\u201313012 (2020).","journal-title":"J. Biol. Chem."},{"key":"6133_CR57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.cell.2015.04.042","volume":"161","author":"A Zomer","year":"2015","unstructured":"Zomer, A. et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161, 1046\u20131057 (2015).","journal-title":"Cell"},{"key":"6133_CR58","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2019.02.009","volume":"18","author":"MA Aksit","year":"2019","unstructured":"Aksit, M. A. et al. Decreased mRNA and protein stability of W1282X limits response to modulator therapy. J. Cyst. Fibros. 18, 606\u2013613 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"6133_CR59","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","volume":"13","author":"EJ Sanderlin","year":"2022","unstructured":"Sanderlin, E. J. et al. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway. Nat. Commun. 13, 2344 (2022).","journal-title":"Nat. Commun."},{"key":"6133_CR60","doi-asserted-by":"crossref","first-page":"22567","DOI":"10.1073\/pnas.1912060116","volume":"116","author":"S Amirbeigiarab","year":"2019","unstructured":"Amirbeigiarab, S. et al. Invariable stoichiometry of ribosomal proteins in mouse brain tissues with aging. Proc. Natl Acad. Sci. USA 116, 22567\u201322572 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6133_CR61","doi-asserted-by":"crossref","first-page":"e2000779","DOI":"10.1371\/journal.pbio.2000779","volume":"15","author":"S Kirchner","year":"2017","unstructured":"Kirchner, S. et al. Alteration of protein function by a silent polymorphism linked to tRNA abundance. PLoS Biol. 15, e2000779 (2017).","journal-title":"PLoS Biol."},{"key":"6133_CR62","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-019-5864-1","volume":"20","author":"C Polte","year":"2019","unstructured":"Polte, C. et al. Assessing cell-specific effects of genetic variations using tRNA microarrays. BMC Genomics 20, 549 (2019).","journal-title":"BMC Genomics"},{"key":"6133_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","volume":"15","author":"AG Durmowicz","year":"2018","unstructured":"Durmowicz, A. G., Lim, R., Rogers, H., Rosebraugh, C. J. & Chowdhury, B. A. The U.S. Food and Drug Administration\u2019s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial. Ann. Am. Thorac. Soc. 15, 1\u20132 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"6133_CR64","doi-asserted-by":"crossref","first-page":"e121159","DOI":"10.1172\/jci.insight.121159","volume":"3","author":"ST Han","year":"2018","unstructured":"Han, S. T. et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI Insight 3, e121159 (2018).","journal-title":"JCI Insight"},{"key":"6133_CR65","first-page":"L928","volume":"310","author":"SE Birket","year":"2016","unstructured":"Birket, S. E. et al. Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy. Am. J. Physiol. 310, L928\u2013939 (2016).","journal-title":"Am. J. Physiol."},{"key":"6133_CR66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.201404-0670OC","volume":"190","author":"SE Birket","year":"2014","unstructured":"Birket, S. E. et al. A functional anatomic defect of the cystic fibrosis airway. Am. J. Respir. Crit. Care Med. 190, 421\u2013432 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"6133_CR67","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature09267","volume":"466","author":"H Guo","year":"2010","unstructured":"Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835\u2013840 (2010).","journal-title":"Nature"},{"key":"6133_CR68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"6133_CR69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-0716-1150-0_12","volume":"2252","author":"A Bartholomaus","year":"2021","unstructured":"Bartholomaus, A. & Ignatova, Z. Codon resolution analysis of ribosome profiling data. Methods Mol. Biol. 2252, 251\u2013268 (2021).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06133-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:11:10Z","timestamp":1687338670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":69,"journal-issue":{"issue":"7966","published-print":{"date-parts":[[2023,6,22]]}},"alternative-id":["6133"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06133-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742667132.793599060","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.I., S.A., N.B. and M.D. are inventors on patents related to tRNA designs for PTC correction. Z.I. is also a scientific advisor for Tevard Biosciences. S.M.R. and G.J.T. are named on an unlicensed patent on the use of OCT for airway surface liquid measurements. S.M.R. is named on an unrelated patent on translational readthrough pharmacotherapy. E.J.S. is a non-voting board member of the Cystic Fibrosis Foundation. The LUNAR technology is proprietary to Arcturus Therapeutics. E.C.A., C.G.P.-G., R.M., B.M., K.K., M.A., K.J.-J.P., G.A., J.A.G., A.S., K.T., P.K., D.M. and P.C. are employees and have securities from Arcturus Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}